Real-World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small-Cell Lung...

Area of Science:

• Oncology
• Clinical Research
• Lung Cancer

Background:

• Small-cell lung cancer (SCLC) often presents as extensive stage (ES) disease.
• Limited treatment options and data exist for third-line (3L) ES SCLC.
• This study evaluated real-world (RW) outcomes and treatment patterns in 3L ES SCLC.

Purpose of the Study:

• To assess clinical outcomes in patients with extensive stage small-cell lung cancer receiving third-line therapy.
• To analyze treatment patterns and identify unmet medical needs in this population.
• To provide real-world data supporting the need for novel therapeutic approaches.

Main Methods:

• Retrospective chart review of adult patients with ES SCLC receiving at least three lines of therapy.
• Exclusion of patients with other malignancies, non-SCLC histology, or those in clinical trials.
• Evaluation of physician-reported response rates, duration of response (DOR), duration of clinical benefit (DoCB), overall survival (OS), and progression-free survival (PFS).

Main Results:

• Among 113 patients, 3L response rates (complete response + stable disease) were low (14%).
• Median DOR, DoCB, OS, and PFS in 3L were 2.8, 2.5, 5.8, and 2.4 months, respectively.
• Platinum-based chemotherapy use significantly decreased from first-line (93-94%) to third-line (16-17%).

Conclusions:

• Real-world findings confirm limited clinical benefit of current therapies in 3L ES SCLC.
• There is a significant unmet need for novel treatments in this patient group.
• The study underscores the necessity for developing new therapies to improve outcomes for difficult-to-treat ES SCLC patients.